Pharmacologic management of neuropsychiatric lupus

Shaye Kivity, Britain Baker, Maria Teresa Arango, Joab Chapman, Yehuda Shoenfeld*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalExpert Review of Clinical Pharmacology
Issue number1
StatePublished - 2 Jan 2016


  • Anti-ribosomal P antibodies
  • cyclophosphamide
  • depression
  • neuropsychiatric lupus
  • systemic lupus erythematosus


Dive into the research topics of 'Pharmacologic management of neuropsychiatric lupus'. Together they form a unique fingerprint.

Cite this